Evaluation of the Efficacy and Safety of Rivaroxaban (BAY 59-7939) for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation.

Trial Profile

Evaluation of the Efficacy and Safety of Rivaroxaban (BAY 59-7939) for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms J-ROCKET-AF
  • Sponsors Bayer
  • Most Recent Events

    • 29 Aug 2016 Results published in Bayer media release
    • 07 Apr 2014 Results from a sub-group analysis published in the Circulation Journal.
    • 27 Jul 2011 Primary endpoint "Stroke and thromboembolism-event-rate has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top